Becton Dickinson stock extends focus on earnings and guidance

Becton Dickinson stock stays centered on its latest earnings backdrop, with fiscal 2025 revenue, margin and cash flow still shaping the valuation case.

Becton Dickinson stock is framed by its last reported fiscal 2025 numbers and its current market value, with the company reporting revenue of $20.9 billion, adjusted diluted EPS of $12.05, and free cash flow of $2.8 billion for fiscal 2025.

Fiscal 2025 numbers matter

The medical technology group, Becton, Dickinson and Company, said fiscal 2025 revenue reached $20.9 billion, while adjusted diluted EPS came to $12.05 and free cash flow reached $2.8 billion. Those figures give the stock a clear operating baseline even without a fresh catalyst in this call.

For investors, the margin and cash conversion profile matter because those are the figures that tend to anchor valuation for large-cap health care hardware names. The business also reported fiscal 2025 results against a backdrop of ongoing scale in consumables, diagnostics and medication delivery.

Revenue of $20.9 billion

The revenue figure of $20.9 billion for fiscal 2025 is the headline number, and it sits beside adjusted diluted EPS of $12.05 and free cash flow of $2.8 billion. Taken together, those metrics show a business with both earnings power and cash generation, which is usually more important than a single-quarter headline for a stock like this.

A separate market read can be built around the companys capital base and scale. Becton Dickinson remains one of the largest listed medtech names in the U.S., and the earnings base from fiscal 2025 gives context for how the shares are priced against that profile.

Cash flow at $2.8 billion

Free cash flow of $2.8 billion in fiscal 2025 is the number that stands out for balance-sheet flexibility and shareholder returns. It also compares with adjusted diluted EPS of $12.05 in the same fiscal year, a useful cross-check on how much of the reported earnings converted into cash.

The companys recent reporting pattern suggests that cash generation is a core part of the investment case rather than a side note. That matters for a mature medtech group because debt service, dividends and deal optionality all lean on that cash engine.

Core product lines still drive the base

Becton Dickinsons product mix is anchored in medication delivery, diagnostic systems and biosciences tools, which together support recurring demand from hospitals, labs and other care settings. The earnings framework from fiscal 2025 indicates that these segments still underpin a business model built on scale and repeat usage.

That product breadth also helps explain why the stock is often evaluated on earnings quality and cash flow rather than only on top-line growth. A company posting $20.9 billion in fiscal 2025 revenue and $2.8 billion in free cash flow has a different profile from a faster-growing but less profitable medtech peer.

Price and market value

The shares are linked here to the companys fiscal 2025 operating base rather than to a fresh intraday move, because the latest available figures in this call are the annual report numbers. The market-cap and quoted-price fields should be read alongside the reported $20.9 billion revenue, $12.05 adjusted EPS and $2.8 billion free cash flow when assessing the stock.

Becton, Dickinson and Company (ISIN US0718131099) closes this note as a large-cap U.S. health care name with a fiscal 2025 revenue base of $20.9 billion, adjusted diluted EPS of $12.05 and free cash flow of $2.8 billion. The trading line and market value can be added once a dated quote is available in the live market feed.

Becton Dickinson company facts

• Company: Becton, Dickinson and Company
• ISIN: US0718131099
• Ticker: NYSE: BDX
• Trading venue: NYSE
• Sector / Industry: Health Care Equipment & Supplies
• Index membership: S&P 500